The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Graves Ophthalmopathy

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Graves Ophthalmopathy

 

High impact information on Graves Ophthalmopathy

 

Chemical compound and disease context of Graves Ophthalmopathy

 

Biological context of Graves Ophthalmopathy

 

Anatomical context of Graves Ophthalmopathy

 

Gene context of Graves Ophthalmopathy

 

Analytical, diagnostic and therapeutic context of Graves Ophthalmopathy

References

  1. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism. Gunji, K., De Bellis, A., Kubota, S., Swanson, J., Wengrowicz, S., Cochran, B., Ackrell, B.A., Salvi, M., Bellastella, A., Bizzarro, A., Sinisi, A.A., Wall, J.R. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
  2. Reevaluating thyrotropin receptor-induced mouse models of graves' disease and ophthalmopathy. Baker, G., Mazziotti, G., von Ruhland, C., Ludgate, M. Endocrinology (2005) [Pubmed]
  3. Messenger RNA expression for a TSH receptor variant in the thymus of a two-year-old child. Paschke, R., Geenen, V. J. Mol. Med. (1995) [Pubmed]
  4. Prenatal treatment of thyrotoxicosis to prevent intrauterine growth retardation. Check, J.H., Rezvani, I., Goodner, D., Hopper, B. Obstetrics and gynecology. (1982) [Pubmed]
  5. 10 years experience with consecutive measurement of thyrotropin binding inhibiting antibodies (TBIAb). Hensen, J., Kotulla, P., Finke, R., Badenhoop, K., Koppenhagen, K., Meinhold, H., Schleusener, H. J. Endocrinol. Invest. (1984) [Pubmed]
  6. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.G., Blomgren, H., Taube, A. N. Engl. J. Med. (1992) [Pubmed]
  7. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. Prummel, M.F., Mourits, M.P., Berghout, A., Krenning, E.P., van der Gaag, R., Koornneef, L., Wiersinga, W.M. N. Engl. J. Med. (1989) [Pubmed]
  8. Has the target autoantigen for Graves' ophthalmopathy been found? McGregor, A.M. Lancet (1998) [Pubmed]
  9. Graves' ophthalmopathy and the TSH receptor. Franklyn, J.A. Lancet (1993) [Pubmed]
  10. Deterioration of severe Graves' ophthalmopathy during cyclosporin treatment. Howlett, T.A., Lawton, N.F., Fells, P., Besser, G.M. Lancet (1984) [Pubmed]
  11. Cyclophosphamide in the management of advanced Graves' ophthalmopathy. A preliminary report. Bigos, S.T., Nisula, B.C., Daniels, G.H., Eastman, R.C., Johnston, H.H., Kohler, P.O. Ann. Intern. Med. (1979) [Pubmed]
  12. Prostaglandin E2 elicits a morphological change in cultured orbital fibroblasts from patients with Graves ophthalmopathy. Smith, T.J., Wang, H.S., Hogg, M.G., Henrikson, R.C., Keese, C.R., Giaever, I. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  13. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. Cao, H.J., Wang, H.S., Zhang, Y., Lin, H.Y., Phipps, R.P., Smith, T.J. J. Biol. Chem. (1998) [Pubmed]
  14. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. Bartalena, L., Marcocci, C., Chiovato, L., Laddaga, M., Lepri, G., Andreani, D., Cavallacci, G., Baschieri, L., Pinchera, A. J. Clin. Endocrinol. Metab. (1983) [Pubmed]
  15. Cell-mediated or humoral immunity in Graves' ophthalmopathy? Profiles of T-cell cytokines amplified by polymerase chain reaction from orbital tissue. McLachlan, S.M., Prummel, M.F., Rapoport, B. J. Clin. Endocrinol. Metab. (1994) [Pubmed]
  16. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Villanueva, R., Inzerillo, A.M., Tomer, Y., Barbesino, G., Meltzer, M., Concepcion, E.S., Greenberg, D.A., MacLaren, N., Sun, Z.S., Zhang, D.M., Tucci, S., Davies, T.F. Thyroid (2000) [Pubmed]
  17. Glycosaminoglycans provide a binding site for thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy. Marinò, M., Lisi, S., Pinchera, A., Marcocci, C., Menconi, F., Morabito, E., Macchia, M., Sellari-Franceschini, S., McCluskey, R.T., Chiovato, L. Thyroid (2003) [Pubmed]
  18. The influence of the exon 1 polymorphism of the cytotoxic T lymphocyte antigen 4 gene on thyroid antibody production in patients with newly diagnosed Graves' disease. Zaletel, K., Krhin, B., Gaberscek, S., Pirnat, E., Hojker, S. Thyroid (2002) [Pubmed]
  19. Peroxisome proliferator-activated receptor-gamma gene expression in orbital adipose/connective tissues is increased during the active stage of Graves' ophthalmopathy. Mimura, L.Y., Villares, S.M., Monteiro, M.L., Guazzelli, I.C., Bloise, W. Thyroid (2003) [Pubmed]
  20. Tissue specificity and serologic reactivity of an autoantigen associated with autoimmune thyroid disease. Ross, P.V., Koenig, R.J., Arscott, P., Ludgate, M., Waier, M., Nelson, C.C., Kaplan, M.M., Baker, J.R. J. Clin. Endocrinol. Metab. (1993) [Pubmed]
  21. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. Bahn, R.S., Dutton, C.M., Natt, N., Joba, W., Spitzweg, C., Heufelder, A.E. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
  22. Human histocompatibility leukocyte antigen-DR and heat shock protein-70 expression in eye muscle tissue in thyroid-associated ophthalmopathy. Hiromatsu, Y., Tanaka, K., Ishisaka, N., Kamachi, J., Kuroki, T., Hoshino, T., Inoue, Y., Wall, J.R., Nonaka, K. J. Clin. Endocrinol. Metab. (1995) [Pubmed]
  23. Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy. Hansen, C., Rouhi, R., Förster, G., Kahaly, G.J. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
  24. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy. Kahaly, G., Diaz, M., Hahn, K., Beyer, J., Bockisch, A. J. Nucl. Med. (1995) [Pubmed]
  25. Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves' ophthalmopathy undergoing orbital radiotherapy. Hofbauer, L.C., Mühlberg, T., König, A., Heufelder, G., Schworm, H.D., Heufelder, A.E. J. Clin. Endocrinol. Metab. (1997) [Pubmed]
  26. Detection of the novel autoantibody (anti-UACA antibody) in patients with Graves' disease. Ohkura, T., Taniguchi, S., Yamada, K., Nishio, N., Okamura, T., Yoshida, A., Kamijou, K., Fukata, S., Kuma, K., Inoue, Y., Hisatome, I., Senju, S., Nishimura, Y., Shigemasa, C. Biochem. Biophys. Res. Commun. (2004) [Pubmed]
  27. Inhibitory effects of Triptolide on interferon-gamma-induced human leucocyte antigen-DR, intercellular adhesion molecule-1, CD40 expression on retro-ocular fibroblasts derived from patients with Graves' ophthalmopathy. Yan, S.X., Wang, Y. Clin. Experiment. Ophthalmol. (2006) [Pubmed]
  28. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. Pasquali, D., Notaro, A., Bonavolonta', G., Vassallo, P., Bellastella, A., Sinisi, A.A. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  29. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Prummel, M.F., Mourits, M.P., Blank, L., Berghout, A., Koornneef, L., Wiersinga, W.M. Lancet (1993) [Pubmed]
  30. Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy. Nocaudie, M., Bailliez, A., Itti, E., Bauters, C., Wemeau, J.L., Marchandise, X. European journal of nuclear medicine. (1999) [Pubmed]
  31. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Salvi, M., Vannucchi, G., Campi, I., Rossi, S., Bonara, P., Sbrozzi, F., Guastella, C., Avignone, S., Pirola, G., Ratiglia, R., Beck-Peccoz, P. Eur. J. Endocrinol. (2006) [Pubmed]
  32. Possible involvement of Fas-mediated apoptosis in eye muscle tissue from patients with thyroid-associated ophthalmopathy. Koga, M., Hiromatsu, Y., Jimi, A., Inoue, Y., Nonaka, K. Thyroid (1998) [Pubmed]
  33. Significance of anti-eye muscle antibody in patients with thyroid-associated ophthalmopathy by quantitative western blot. Hiromatsu, Y., Sato, M., Tanaka, K., Shoji, S., Nonaka, K., Chinami, M., Fukazawa, H. Autoimmunity (1992) [Pubmed]
 
WikiGenes - Universities